Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J signs $1.385bn deal with Elan for Alzheimer's program

Executive Summary

Johnson & Johnson has formed a joint venture with Elan Corp. PLC that will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program, an alliance that originated in 2000 between Elan and partner Wyeth (since acquired by Pfizer).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Joint Venture

Related Companies

Advertisement
UsernamePublicRestriction

Register